2014

WuXi PharmaTech Schedules Second-Quarter 2013 Earnings Release

SHANGHAI, July 15, 2013 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device R&D outsourcing company with operations in China and the United States, today announced that it will release financial results for the second quarter of 2013 after the New York Stock Exchange closes on Monday, August 12, 2013 (which will be Tuesday morning, August 13, 2013 Shanghai time). The earnings release will be available on the investor relations section of the Company's website at http://www.wuxiapptec.com/.

Following the earnings announcement, WuXi PharmaTech senior management will host a conference call at 8:00 am (U.S. Eastern) / 5:00 am (U.S. Pacific) / 8:00 pm (Beijing/Shanghai/Hong Kong) on Tuesday, August 13, 2013, to discuss the second-quarter 2013 financial results and recent business activities. The conference call may be accessed by calling:

Australia 

1800 801 825

Belgium            

0800 784 01

Canada             

1855 842 3490

China                

4001 200 539

France              

0800 916 599

Germany          

0800 1899 399

Hong Kong       

800 905 927

Hong Kong (toll)         

+852 5808 3202

India                  

000 800 100 8255

Indonesia         

00180 301 91840

Ireland              

1800 720 105

Italy         

800 875 577

Japan                

0120 271 900

Malaysia 

1800 816 107

Netherlands    

0800 0234 240

New Zealand  

0800 452 905

Singapore        

800 616 3222

South Korea    

00798 6136 1434

Sweden            

0207 968 70

Switzerland     

0800 837 001

Taiwan              

0080 161 5189

United Kingdom      

0800 015 9725

United Kingdom—London (toll)    

44 (0) 20 3078 7622

United States 

1855 298 3404

United States—New York (toll)

+1 631 5142 526

Other countries (toll)         

+65 6823 2299

Conference ID:        

1007691

A telephone replay will be available two hours after the call's completion at:

Australia 

1800 008 585

Belgium  

0800 11 797

Canada   

1866 4783 460

China       

4001 842 240

France     

0800 904 160

Germany

0800 181 3763

Hong Kong       

800 966 697

India        

000 800 100 6647

Indonesia         

0018 0306 12086

Ireland    

1800 511 665

Italy

800 784 706

Japan       

0066 3386 1031

Malaysia 

1800 181 061

Netherlands    

08000 232 153

New Zealand  

0800 444 310

Singapore        

800 616 2127

South Korea    

00798 612 1058

Sweden   

020 792 274

Switzerland     

0800 564 016

Taiwan    

00801 232 352

United Kingdom      

0800 169 7301

United States 

1866 846 0868

Conference ID:        

1007691

A live webcast of the conference call and replay will be available in the investor relations section of WuXi PharmaTech's website at http://www.wuxiapptec.com/.

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec.

For more information, please contact:

Ronald Aldridge
Director of Investor Relations
WuXi PharmaTech (Cayman) Inc.
Tel: +1-201-585-2048
Email: Ron_Aldridge@wuxiapptec.com
Web: http://www.wuxiapptec.com

 

SOURCE WuXi PharmaTech (Cayman) Inc.



RELATED LINKS
http://www.wuxiapptec.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.